Tenacia and Golden Age Health Partner to Commercialise Ztalmy for CDKL5 Deficiency Disorder in China
Tenacia Biopharmaceuticals has granted Golden Age Health exclusive rights to commercialise Ztalmy, the first approved therapy for CDKL5 deficiency disorder, in Mainland China.
Ztalmy | 03/02/2026 | By News Bureau | 140
Immedica Announces Acquisition of Marinus Pharmaceuticals
The acquisition complements and further strengthens Immedica’s global rare disease business by adding ZTALMY® (ganaxalone) oral suspension, CV, a neuroactive steroid gamma-aminobutyric acid (GABA)-A receptor positive modulator, approved by the U.S. Food and Drug Administration (FDA) in March 2022.
ZTALMY | 31/12/2024 | By Aishwarya | 363
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy